Expert Market is an online platform expert in supplies, software, and services for business.

Welcome to Expert on Nothing with Natasha Wakefield--a space for the curious and those on a journey to becoming their best selves. From fitness and mental health to relationships, beauty and everything in between, I ask the questions you're thinking, so you don't have to

Impact Factor: 4.9 (2024) Aims of the journal: It provides a forum for the commentary and analysis of drug discovery in the post-genomic era, with emphasis placed on the current and emerging disciplines involved and strategic planning. It is international, MEDLINE-indexed and peer-reviewed that publishes review articles covering all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. Content: It covers chemoinformatics reviews - bioinformatics; assay development; novel screening technologies, in vitro/in vivo models, structure-based drug design, systems biology and drug case histories examining the steps involved in the preclinical and clinical development. Readership: Scientists and healthcare and pharmaceutical managers, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents.

Impact Factor: 0.464 (© 2015 Thomson Reuters, Journal Citation Reports®) Circulation: The Publisher does not disclose the circulation. Aims of the Journal: Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs. The Editors welcome: Reviews that focus on rare diseases or orphan drugs, and report on any of the following topics: diagnostics, pharmacogenomics and screening; prevalence and epidemiology (with particular attention to regional variations); drug development; lead generation and discovery; early or late phase clinical trials; regulatory issues; post-marketing safety; treatment outcomes. Drug Evaluations specifically reviewing the pharmacological properties; clinical potential/clinical efficacy; safety and, if applicable, HE/OR data on a particular orphan drug. Original Research papers reporting the results of early or late stage clinical investigations or HE/OR data on orphan drugs and studies in the treatment of rare diseases. Editorials, commentaries and meeting-highlights papers covering topics in rare diseases. Instructions for Authors / Submission Guidance: This can be found here

Impact Factor: 4.626 (Source: 2015 ISI) Journal Ranking:  4/59 Chemistry, Medicinal; 31/253 Pharmacology & Pharmacy. Source: Thomson Reuters Journal Citation Reports 2015 Circulation: The Publisher does not disclose the circulation. Aims of the journal: Expert Opinion on Therapeutic Patents is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on recent pharmaceutical patent claims, providing expert opinion the scope for future development, in the context of the scientific literature. Readership: The audience consists of scientists, managers and decision-makers in the pharmaceutical industry and others closely involved in R&D. Content: The Editors welcome: Reviews covering recent patent claims on compounds or applications with therapeutic potential, including biotherapeutics and small-molecule agents with specific molecular targets; and patenting trends in a particular therapeutic area Patent Evaluations examining the aims and chemical and biological claims of individual patents Perspectives on issues relating to intellectual property Manuscript submission: Instructions for authors can be viewed here Online submission here

Impact Factor: 4.798 (Source: Thomson Reuters Journal Citation Reports 2015) Journal Ranking: 28/253 Pharmacology & Pharmacy (Source: Thomson Reuters Journal Citation Reports 2015) Circulation: A figure is not disclosed. Distribution: It is available via subscription.  Aims of the Journal: The journal evaluates molecules, signal pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and should not include clinical information on specific drugs. Expert Opinion on Therapeutic Targets is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on novel molecular targets, with the aim of providing expert opinion on the scope for future drug development and the impact on drug discovery.  Editors welcome reviews covering novel disease targets at the molecular level and their implications for future drug development and original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs. Readership: Scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D. Manuscript Submission: Information for contributors can be found here and here. Other information: There is no generic email address. The Editorial Board can be found here.

Do you want to build a bullet-proof business in today’s cancel culture - following the Bible as your roadmap to success? How about owning a business without it owning you, and thriving in your personal relationships as well as your professional ones? The Benham Brothers are here to help - along with their award-winning Expert Ownership team! Nationally-acclaimed entrepreneurs and best-selling authors, David and Jason Benham, share their more than 40 years of business experience to show you how to achieve financial freedom, enjoy relational success, and have a bold impact in today’s “easy to offend” culture. These twin brothers were the OG’s of cancel culture when their HGTV show was canceled back in 2014 for their Christian values. Yet they stood strong and continued to thrive in business without a scratch, and now they’re here to help you do the same.If you’re ready to "fight the good fight" with guys who pull no punches for fear of being politically incorrect, this podcast is for you!

Impact factor: 3.542 (Thomson Reuters, Journal Citation Reports) Journal Ranking: 59/253 Pharmacology and Pharmacy (Source: Publisher) Circulation: The publisher does not disclose the circulation. Aims of the Journal: Expert Review of Anti-infective Therapy aims to provide reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests. Content: The Expert Review format endeavours to provide an overview of current thinking in a key area of anti-infective research or clinical practice. It includes the following sections: Expert Commentary - a personal view on the most effective or promising strategies Five-year view - a perspective of future prospects within a realistic time scale Key issues - a summary cutting to the author's most critical points Manuscript Submission: Unsolicited manuscripts are accepted for publication in the journal; please contact the Commissioning Editor with a brief proposal and article outline. All articles are subject to rigorous peer-review. Author guidelines can be viewed here. Online manuscript submission can be found here. Ad Rates: Further information on ad rates can be found here.

Impact Factor: 2.094 (Source: 2015 Thomson Reuters, Journal Citation Reports). Journal Ranking: 150/213 (Oncology) - (Source: Publisher) Circulation: The Publisher does not disclose the circulation. Aims of the Journal: Expert Review of Anticancer Therapy provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. Content: Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: - Expert Commentary: a personal view on the most effective or promising strategies - Five-year view: a clear perspective of future prospects within a realistic time-scale - Key issues: an executive summary cutting to the author's most critical points Readership: The journal is aimed at doctors and Health professionals working in Oncology mainly. Manuscript Submission: Articles published in the journal are commissioned by the Editor in collaboration with the Editorial Advisory Board. All articles are subject to rigorous peer-review. Author guidelines can be found here. Online manuscripts submission can be found here. Ad Rates: Advertising information can be found here.

Impact Factor: 2.596 (Source: Publisher) Journal Ranking: 83/150 (Immunology) (Source: 2015 Journal Citation Reports, Thomson Reuters 2016) Circulation: The figure is not currently disclosed. Frequency: Published 12 times a year. Aims of the journal: Expert Review of Clinical Immunology aims to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Content: Articles focus on the following key areas: Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines Performance and benefits of newly approved therapeutic agents New diagnostic approaches Screening and patient stratification Pharmacoeconomic studies New therapeutic indications for existing therapies Adverse effects, occurrence and reduction Prospects for medicines in late-stage trials approaching regulatory approval Novel treatment strategies Epidemiological studies Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases. Editorial contacts: See the full list of editorial contacts here Manuscript Submission: See author guidelines here Access online submission portal here Other information: To discuss advertising & sponsorship needs, contact Per Sonnerfeldt at per.sonnerfeldt@informa.com.